What is the prevalence of intensive care unit‑acquired weakness in the ICU population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prevalence of ICU-Acquired Weakness in the ICU Population

The overall prevalence of ICU-acquired weakness (ICUAW) in the general ICU population is approximately 33%, based on systematic analysis of 31 prospective studies involving 3,095 critically ill patients. 1

Overall Prevalence Data

The most authoritative data comes from the 2014 American Thoracic Society Clinical Practice Guideline, which conducted a comprehensive systematic review specifically addressing this question. Among 3,095 patients evaluated across 31 studies (predominantly prospective cohort studies), 1,019 patients (33%) developed ICUAW. 1 This represents the most robust pooled estimate available from high-quality prospective research.

Prevalence Varies by Population and Risk Factors

The prevalence of ICUAW is not uniform across all ICU populations—it varies substantially based on specific patient characteristics and exposures:

High-Risk Populations

  • Severe sepsis patients: 64% prevalence (262 patients across 7 studies), significantly higher than other patient groups at 30% (P < 0.001) 1
  • Prolonged mechanical ventilation:
    • 33% in patients ventilated <5 days
    • 43% in patients ventilated >7 days (P = 0.01) 1
  • COVID-19 ICU patients: 55% prevalence (868 patients across 8 studies), representing a notably elevated risk 2

Duration of Mechanical Ventilation Impact

The longer the exposure to mechanical ventilation, the higher the incidence of ICUAW. Patients diagnosed with ICUAW had median ventilation duration of 25 days (IQR 12-33 days) versus 18 days (IQR 8-18.5 days) in those without ICUAW (P = 0.06). 1

Methodological Considerations Affecting Reported Prevalence

The diagnostic method used significantly impacts reported prevalence rates:

  • Clinical examination (MRC score): 32% prevalence (413/1,276 patients, 95% CI 30-35%) 3
  • Electrophysiological testing: 47% prevalence (749/1,591 patients, 95% CI 45-50%) 3

This discrepancy exists because approximately 25% of ICU patients cannot comply with clinical evaluation due to altered consciousness or sedation, potentially leading to underreporting when relying solely on physical examination. 3

Contemporary Evidence

More recent research confirms these prevalence estimates remain consistent:

  • A 2015 systematic review reported 40% incidence (1,080/2,686 patients, 95% CI 38-42%) in heterogeneous ICU populations, largely including patients on mechanical ventilation ≥7 days 3
  • A 2020 single-center study found nearly 50% of ICU-admitted patients developed ICUAW 4
  • A 2023 cross-sectional study reported 16.8% incidence, though this lower figure likely reflects a less selected population 5

Clinical Context

The 33% overall prevalence figure represents the best estimate for general ICU populations, but clinicians should recognize that specific patient subgroups face substantially higher risk. Patients with severe sepsis, those requiring prolonged mechanical ventilation (>7 days), and COVID-19 patients in the ICU have prevalence rates approaching or exceeding 50-60%. 1, 2

The variation in reported prevalence (ranging from 16% to 80% across different studies) reflects differences in patient selection criteria, diagnostic methods employed, timing of assessment, and specific ICU populations studied. 6, 5 The ATS guideline's 33% figure from prospective studies with explicit diagnostic criteria provides the most reliable benchmark for clinical reference. 1

References

Related Questions

Why should high positive end‑expiratory pressure (PEEP) be avoided in patients with neuromuscular weakness, and how does PEEP increase their work of breathing?
What is the recommended dosing of sultamicillin 750 mg for adult infections, including adjustments for renal impairment?
Do coagulase-negative Staphylococcus species appear as cocci in chains on Gram stain?
What are the detailed pharmacokinetic properties of amisulpride, including absorption, bioavailability, distribution, metabolism, elimination, half-life, and dosing considerations in renal impairment?
Is hydrochlorothiazide safe for patients with pulmonary hypertension?
How long does imiquimod (5% cream) take to reduce genital warts in an adult male?
Should a patient taking memantine to reduce Adderall (amphetamine/dextroamphetamine) tolerance have a drug holiday from memantine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.